Literature DB >> 28075611

What the Radiologist Should Know About Treatment of Peritoneal Malignancy.

Emily A Aherne1, Helen M Fenlon1, Conor J Shields2, Jurgen J Mulsow2, Carmel G Cronin1.   

Abstract

OBJECTIVE: The purpose of this article is to discuss the role of the radiologist in the treatment of peritoneal cancer, with focus placed on advanced treatment options and selection of patients with resectable disease for whom complete cytoreduction can be achieved.
CONCLUSION: Peritoneal cancers traditionally have been associated with significant morbidity and universal mortality; however, the management of such cancers has evolved substantially. Advanced treatment options, including cytoreductive surgery and intraperitoneal chemotherapy, are associated with significantly improved long-term patient survival. To ensure that patients benefit from aggressive multimodality treatments, the radiologist plays a pivotal role in the multidisciplinary team to ensure careful patient selection, identifying individuals with resectable disease for whom complete cytoreduction can be achieved.

Entities:  

Keywords:  CT; HIPEC; MRI; PET/CT; cytoreductive surgery; peritoneal cancer; peritoneal malignancy

Mesh:

Year:  2017        PMID: 28075611     DOI: 10.2214/AJR.16.16646

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  6 in total

Review 1.  The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review.

Authors:  Bradley Carlson; Carla Harmath; Kiran Turaga; Hedy L Kindler; Samuel G Armato; Christopher Straus
Journal:  Abdom Radiol (NY)       Date:  2022-03-07

Review 2.  Peritoneal malignancy: anatomy, pathophysiology and an update on modern day imaging.

Authors:  Jack W Power; Philip J Dempsey; Andrew Yates; Helen Fenlon; Jurgen Mulsow; Conor Shields; Carmel G Cronin
Journal:  Br J Radiol       Date:  2021-12-08       Impact factor: 3.629

3.  Adding Value of MRI over CT in Predicting Peritoneal Cancer Index and Completeness of Cytoreduction.

Authors:  Chia-Ni Lin; Weh-Shih Huang; Tzu-Hao Huang; Chao-Yu Chen; Cheng-Yi Huang; Ting-Yao Wang; Yu-San Liao; Li-Wen Lee
Journal:  Diagnostics (Basel)       Date:  2021-04-08

4.  CT Enterography for Preoperative Evaluation of Peritoneal Carcinomatosis Index in Advanced Ovarian Cancer.

Authors:  Katty Delgado-Barriga; Carmen Medina; Luis Gomez-Quiles; Santiago F Marco-Domenech; Javier Escrig; Antoni Llueca
Journal:  J Clin Med       Date:  2022-01-18       Impact factor: 4.241

5.  Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group.

Authors:  Sohei Satoi; Naminatsu Takahara; Tsutomu Fujii; Hiroyuki Isayama; Suguru Yamada; Yasushi Tsuji; Hideyo Miyato; Hironori Yamaguchi; Tomohisa Yamamoto; Daisuke Hashimoto; So Yamaki; Yousuke Nakai; Kei Saito; Hayato Baba; Toru Watanabe; Shigeto Ishii; Masamichi Hayashi; Keisuke Kurimoto; Hideaki Shimada; Joji Kitayama
Journal:  J Hepatobiliary Pancreat Sci       Date:  2022-01-07       Impact factor: 3.149

Review 6.  Ovarian cancer staging: What the surgeon needs to know.

Authors:  Lucas Roberto Lelis Botelho de Oliveira; Natally Horvat; Pamela Ines Causa Andrieu; Pedro Sergio Brito Panizza; Giovanni Guido Cerri; Publio Cesar Cavalcante Viana
Journal:  Br J Radiol       Date:  2021-07-21       Impact factor: 3.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.